Le Lézard
Classified in: Health
Subjects: CCA, FVT

DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call


DENVER, April 17, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.

This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: 

Thursday, May 2, 2024
Starting at 5:00 p.m. EDT
Webcast can be accessed using this link 
Dial in number: 877-918-6630
International dial in: 517-308-9042

When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey?from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of December 31, 2023, DaVita served approximately 250,200 patients at 3,042 outpatient dialysis centers, of which 2,675 centers were located in the United States and 367 centers were located in 11 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact Information 
Investors:
[email protected]

DaVita Logo (PRNewsfoto/DaVita)

 

SOURCE DaVita


These press releases may also interest you

at 06:45
Future Market Insights (FMI) predicts a robust future for the scaffold technology market. This growth is primarily driven by advancements in tissue engineering and regenerative medicine. As these fields develop, demand for innovative scaffold...

at 06:45
Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's disease in...

at 06:40
Associated Medical Professionals of NY (A.M.P.) is pleased to announce that internationally recognized radiation oncology physician, researcher and thought leader Steven E. Finkelstein, M.D., DABR, FACRO, has joined its care team as Director of the...

at 06:30
  All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmedMathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board...

at 06:30
Company delivers strong first quarter results:Sales of $8.0 billion, down 0.3% YoY; adjusted sales of $7.7 billion with organic growth up ~1% YoYGAAP earnings per share of $1.67, down 5% YoY; adjusted earnings of $2.39, up double digits...

at 06:30
...



News published on and distributed by: